Abstract:Objective To investigate the role of serum chromogranin A (CgA) determination for neuroendocrine neoplasma (NEN) . Methods In 63 patients with NEN (NEN group) , 16 patients with gastrointestinal and pancreatic tumors (digestive system tumor group) and 30 healthy subjects (healthy control group) Serum CgA levels and carbohydrate antigen (CA) 19-9 levels were determined. The clinicopathological characteristics (sex, age, the primary site of tumors, the grade of tumors and the presence or absence of distant metastasis) of NEN patients were recorded. The efficiency of serum CgA for the diagnosis of NEN was evaluated by receiver operating characteristic (ROC) curve. Results Serum CgA level in NEN group was higher than those in digestive system tumor group and healthy control group (P<0.05) , and there was no statistical significance between digestive system tumor group and healthy control group (P>0.05) . Serum CgA level in NEN patients with distant metastasis was higher than that without distant metastasis (P<0.05) .There was no statistical significance for serum CgA levels in patients with different sex, ages, the primary sites of tumors and the grades of tumors (P>0.05) . ROC curve analysis showed that the area under curve (AUC) of serum CgA in the diagnosis of NEN was 0.989, the optimal cut-off value was 47.31 ng/mL, the sensitivity was 95.5％, and the speci?city was 92.3％. Using digestive system tumor group as control, the AUC of serum CgA for the differential diagnosis of NEN was 0.948, the optimal cut-off value was 50.97 ng/mL, the sensitivity was 84.8％, and the speci?city was 90.9％. The AUC of serum CgA combined with CA19-9 was 0.956, the sensitivity was 90.5％, and the speci?city was 81.8％. Compared with the results of preoperation, serum CgA level decreased in 25 of 32 NEN patients after operation (P<0.05) . There was no statistical signi?cance for serum CgA level before and after operation in the 7 patients (P<0.05) . Conclusions CgA can be used for the assistant diagnosis and therapeutic monitoring of NEN, and it plays a role in predicting tumor metastasis.

Significance of Chromogranin A in Diagnosis and Prognosis of Neuroendocrine Tumors

Circulating Chromogranin A As A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors.

Chromogranin A and serotonin for evaluation of treatment efficacy of neuroendocrine tumors

A Comparative Analysis of Chromogranin A and Inflammatory Cytokines in Patients with Neuroendocrine Tumors

Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study

Use of Chromogranin A for Monitoring Patients with Pancreatic Neuroendocrine Neoplasms

Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages

Basic Research and Clinical Significance of Chromogranin A

Chromogranin A as a diagnostic marker of pheochromocytoma and paraganglioma: A systematic review and meta‐analysis

Role of serum CgA determination for neuroendocrine neoplasma

A Critical Approach to Clinical Biochemistry of Chromogranin A

Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls

Circulating Chromogranin A as Surveillance Biomarker in Patients with Carcinoids – The CASPAR Study

Chromogranin A in human neuroendocrine tumors: an immunohistochemical study with region-specific antibodies

The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.

Performance of double-antibody sandwich ELISA for chromogranin A determination

Secretagogin, a Novel Neuroendocrine Marker, Has a Distinct Expression Pattern from Chromogranin A

Circulating miRNA Increases the Diagnostic Accuracy of Chromogranin A in Metastatic Pancreatic Neuroendocrine Tumors

Prognostic role of chromogranin A in castration-resistant prostate cancer: A meta-analysis.

Combined test of serum CgA and NSE improved the power of prognosis prediciton of NF-pNETs.

Expression of amino acid sequences of the chromogranin A molecule and synaptic vesicle protein 2 in neuroendocrine tumors of the lung